Tag Archives: Parkinson’s

Acadia Outsources Compassion and Math

On their quarterly call, Acadia Pharmaceuticals announced the pricing for Nuplazid, freshly approved by the FDA for the treatment of Parkinsonian psychosis (PDP). The price has been set at $1950 per month, about $23,400 per year. A quick scan of … Continue reading

Posted in Big Pharma, BioFollies, Biotech | Tagged , , | 1 Comment

The Vision Thing

Putting all of one’s corporate chips on a single therapeutic program is seldom, if ever, a wise strategy. Even if the product moves forward, a company’s longterm viability depends on a periodically replenished pipeline. While this is a well-documented dynamic … Continue reading

Posted in Uncategorized | Tagged , , , | Leave a comment

Two CNS Acquisitions

Two companies had buyouts announced today: One is clearly good news, the second may be good for shareholders, we are not sure about the ramifications for its CNS work. 1) Newron is acquiring neurogenesis-specialist NeuroNova for about $20 million in … Continue reading

Posted in Uncategorized | Tagged , , , , , | Leave a comment